Form 4: Trevi Therapeutics CFO Granted Stock Options
SEC Form 4 Filing
Lisa Delfini, CFO of Trevi Therapeutics, was granted stock options to purchase 225,500 shares of common stock on February 18, 2025.
Summary
- Lisa Delfini, the Chief Financial Officer of Trevi Therapeutics, Inc., was granted stock options on February 18, 2025.
- The options allow her to purchase 225,500 shares of Trevi Therapeutics' common stock at an exercise price of $4.22 per share.
- The options vest as to 25% of the shares on February 18, 2026, and the remaining 75% vest in equal monthly installments through February 18, 2029.
- The options expire on February 17, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value.
Positives
- The granting of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
- The vesting schedule encourages long-term commitment from the CFO.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation strategy.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, indicating that the company is investing in its leadership.
- Employees may see this as a positive sign of the company's commitment to its executives.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of the stock option grant |
| 02/18/2026 | Date when 25% of the stock options vest |
| 02/18/2029 | Date when the remaining 75% of the stock options are fully vested |
| 02/17/2035 | Expiration date of the stock options |
| 02/20/2025 | Date of the Form 4 filing |
Keywords
stock options, Trevi Therapeutics, CFO, Lisa Delfini, equity compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.